Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer


Perillyl alcohol (POH) is a naturally occurring lipid with preclinical activity against mammary carcinomas. We conducted a phase II multi-institutional study of oral POH administered four times daily in women with advanced treatment-refractory breast cancer. Eligible women were treated with POH four times daily at 1,200–1,500 mg m−2 dose−1 on a 28-day cycle… (More)
DOI: 10.1007/s00280-007-0585-6


5 Figures and Tables